Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;24(1):2296.
doi: 10.1186/s12889-024-19691-4.

Pre-exposure prophylaxis (PrEP) use trajectories and incidence of HIV and other sexually transmitted infections among PrEP users in Belgium: a cohort analysis of insurance claims data from 2017 to 2019

Anke Rotsaert  1 , Tom Smekens  2 , David Jaminé  3 , Tonio Di Zinno  3 , Jessika Deblonde  4 , Marie-Laurence Lambert  5 , Eric Florence  6   7 , Thijs Reyniers  2 , Jef Vanhamel  2 , Catherine Lucet  8 , Maarten Schim van der Loeff  9   10   11   12 , Bernadette Hensen  2 , Bea Vuylsteke  2
Affiliations

Pre-exposure prophylaxis (PrEP) use trajectories and incidence of HIV and other sexually transmitted infections among PrEP users in Belgium: a cohort analysis of insurance claims data from 2017 to 2019

Anke Rotsaert et al. BMC Public Health. .

Abstract

Background: Since June 2017, oral pre-exposure prophylaxis (PrEP) has been reimbursed in Belgium for people at substantial risk of HIV. To inform the national PrEP programme, we described sociodemographic characteristics of PrEP users, PrEP dispensing practices, testing for HIV and sexually transmitted infections (STIs; gonorrhoea, chlamydia and syphilis), and incidence of HIV and STIs.

Methods: Analysis of routinely collected social health insurance claims data from all individuals who were dispensed at least one PrEP prescription between June 2017 and December 2019. Using logistic regression adjusted for age, we examined associations between sociodemographic characteristics and having been dispensed PrEP only once in the first six months of PrEP use.

Results: Overall, 4559 individuals were dispensed PrEP. Almost all PrEP users were male (99.2%, 4522/4559), with a median age of 37 years (IQR 30-45). A minority were entitled to an increased healthcare allowance (11.4%, 514/4559). 18% (657/3636) were dispensed PrEP only once in the first six months of PrEP use. PrEP users younger than 25 years, unemployed, entitled to an increased healthcare allowance, and who initiated PrEP between January 2019 and June 2019 were more likely to have had no PrEP dispensing after initiation compared to their counterparts. The testing rates for bacterial STIs and HIV were 4.2 tests per person-year (95% CI 4.1-4.2) and 3.6 tests per person-year (95% CI 3.5-3.6), respectively. Twelve individuals were identified to have seroconverted during the study period, resulting in an HIV incidence rate of 0.21/100 person-years (95% CI 0.12-0.36). The incidence of bacterial STIs was 81.2/100 person-years (95% CI 78.7-83.8).

Conclusions: The study highlights challenges in PrEP persistence and a high incidence of bacterial STIs among individuals receiving PrEP. Tailored prevention support is crucial for individuals with ongoing HIV risk to optimise PrEP effectiveness. Integrated STI testing and prevention interventions within PrEP care are necessary to mitigate STI acquisition and transmission among PrEP users.

Keywords: Claims data; HIV incidence; HIV prevention; Longitudinal; Pre-exposure prophylaxis (PrEP); STI.

PubMed Disclaimer

Conflict of interest statement

The institution of M. F. Schim van der Loeff received study funding from Sanofi Pasteur MSD, Janssen Infectious Diseases and Vaccines and GSK; he was a co-investigator in a Merck-funded investigator-initiated study; he was an investigator on a Sanofi Pasteur MSD sponsored trial; he served on advisory boards of GSK and Merck. The institution of TR received fees from GSK/ViiV for attending advisory boards. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Trajectories of individuals who seroconverted after PrEP initiation, indicated by letter codes (A through L), in Belgium, between 1 June 2017 and 31 December 2019 (N = 12). ART: antiretroviral treatment, PEP: post-exposure prophylaxis, PrEP: pre-exposure prophylaxis. The numbers indicate the number of pills dispensed per PrEP dispensing event. PrEP initiation was defined as first PrEP dispensing date
See this image and copyright information in PMC

References

    1. UNAIDS. UNAIDS global AIDS update 2022: in danger [Internet]. 2022 [cited 2022 Dec 19]. p. 373. https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-...
    1. European Centre for Disease Prevention and Control, World Health Organization. HIV/AIDS surveillance in Europe 2022. 2021 data [Internet]. 2022 [cited 2022 Dec 19]. https://www.ecdc.europa.eu/sites/default/files/documents/2022-Annual_HIV...
    1. Sciensano. Epidemiologie van AIDS en hiv-infectie in België - rapport 2022, toestand op 31 december 2021 [Internet]. 2022 [cited 2022 Dec 19]. https://www.sciensano.be/sites/default/files/rapport_hiv_2022_nl.pdf
    1. BCFI | Terugbetaling [Internet]. [cited 2022 Aug 11]. https://www.bcfi.be/nl/ampps/159483?cat=b
    1. UNAIDS, Global. AIDS strategy 2021–2026 End inequalities. End AIDS. Geneva, Switzerland; 2022.

Publication types

LinkOut - more resources